Athira Pharma GAAP EPS of -$0.89 misses by $0.20
Athira Pharma reported a Q3 GAAP EPS of -$0.89, missing estimates by $0.20. The company's cash position decreased to $32.3M as of September 30, 2026, from $88.3M at the end of 2025, with net cash used in operations rising to $18.98M for the quarter, up from $4.7M a year prior.
How this was made
The 30-second read
Why it matters
A GAAP EPS miss combined with a large reduction in cash and investments can shift expectations toward higher dilution risk or near-term capital needs.
Market read
Traders can reassess near-term risk for LONA based on the earnings miss and the reported cash drawdown.
What to watch
The excerpt lacks guidance, trial catalysts, and financing plans; traders may overreact without knowing whether the company has runway or upcoming milestones.
Background
The piece summarizes Athira Pharma’s Q3 GAAP EPS result and liquidity position as of Sept. 30, 2026.
Ticker impact
Athira Pharma reported Q3 GAAP EPS of -$0.89, missing by $0.20, alongside a sharp decline in cash versus year-end 2025.
Likely downward pressure as traders price in higher funding risk and weaker operating trajectory.
The article provides the company’s own GAAP EPS miss and a large drop in cash and investments, which typically weighs on micro-cap biotech sentiment and risk appetite.
Market effects
Reinforces broader biotech financing sensitivity to cash burn and GAAP losses, potentially pressuring similar pre-revenue names.
Limited, company-specific impact likely confined to US micro-cap biotech sentiment.
Low, no cross-market policy or macro linkage indicated.
Counterpoint
If the cash decline reflects timing of working-capital movements rather than ongoing burn, the liquidity risk may be overstated.
Key entities
- companyAthira Pharma
US-listed biotech issuer reporting Q3 GAAP EPS and cash position changes.
- companyLeonaBio, Inc.
The article’s byline entity; not the subject of the earnings figures.


